BAYER AG NA O.N.
Commented by Stefan Feulner on June 23rd, 2022 | 10:14 CEST
ThyssenKrupp, Desert Gold, Bayer - Waiting for the turnaround
After a strong start to the week for the DAX and a high of 13,444 points, the leading German index ran out of steam. Due to increasing fears of a recession and concerns about continued enormously high inflation rates, the stock market barometer again fell below the psychologically important mark of 13,000 points. The speech of the head of the US Federal Reserve, Jerome Powell, should therefore be enormously important for the further course and provide for volatile markets. A decision is also likely to be made soon on the gold market based on the strategy of the monetary guardians.
Read
Commented by Nico Popp on June 22nd, 2022 | 13:01 CEST
Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer
Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.
Read
Commented by Carsten Mainitz on June 8th, 2022 | 11:35 CEST
Valneva, Defence Therapeutics, Bayer - Blockbusters: Turbos for your share portfolio!
Blockbusters are drugs with which companies generate sales of more than USD 1 billion per year. Corona vaccines are currently an integral part of the global hit list. But also many application areas in different cancer fields or cardiovascular diseases offer a large market worth billions. Like BioNTech, a company with the right pipeline and the resulting compounds can quickly evolve from a start-up into an established and profitable player.
Read
Commented by Armin Schulz on June 3rd, 2022 | 10:49 CEST
Bayer, Globex Mining, RWE - Diversified shares perform strongly in tough times
Going all-in is extremely risky on the stock market. Because in the long run, you are not always right with your estimates, so a poor trade can quickly tear down the good performance. For example, a better approach would be to diversify the portfolio, spreading the investment over 10 different companies. Two big winners are enough to more than absorb several total losses. Those who want even more security can add stocks to their portfolio that are already diversified. Today we will take a closer look at three companies of this kind.
Read
Commented by Nico Popp on May 17th, 2022 | 09:54 CEST
Alzheimer's share? Ask the CEO! Valneva, NervGen Pharma, Bayer
High blood pressure, diabetes, stroke and Alzheimer's disease are scourges of our time. As people in industrialized countries grow older, it becomes increasingly likely that they will also suffer from one of these diseases. While there is likely to be a genetic predisposition for all of the ailments mentioned, lifestyle also plays a role. Lack of exercise and obesity often leads first to high blood pressure, then to diabetes, and ultimately to even worse conditions. In the event of a pandemic, all people with such pre-existing conditions belong to a high-risk group. Reason enough to take a closer look at stocks related to these issues and ask how investors can profit.
Read
Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST
Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead
No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...
Read
Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST
Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus
Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?
Read
Commented by Juliane Zielonka on April 21st, 2022 | 13:58 CEST
Bayer AG, Perimeter Medical, Twitter - Shareholder interests drive share price performance
The life science and medical technology sectors offer investment opportunities. Whether with old hands like Bayer AG or up-and-coming innovative startups like Perimeter Medical, each company has its own fascination. Strong corporate management that acts in the interests of shareholders provides additional confidence. The latter, in particular, is currently being put to the test at the short messaging service Twitter. Elon Musk's takeover bid threatens to dilute existing investors' shares with a poison pill.
Read
Commented by Nico Popp on April 20th, 2022 | 12:04 CEST
Where the music is playing now: BioNTech, MAS Gold, Bayer
Capitalism is the best system when it comes to distributing goods effectively. Supply and demand first make scarce goods expensive and then turn them into a promising business area. That is what happened with vaccines. Today, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is warning of an oversupply of Corona vaccines - two years ago, things looked very different. While biotech stocks such as BioNTech are being penalized, it is important to identify tomorrow's opportunities. Scarcity plays an important role here.
Read
Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST
Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation
The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.
Read